Allogeneic blood stem cell transplantation of high-risk patients after conditioning with treosulfan and fludarabine

被引:2
|
作者
Casper, J [1 ]
Wilhelm, S [1 ]
Steiner, B [1 ]
Wolff, D [1 ]
Grobe, N [1 ]
Hähling, D [1 ]
Hartung, G [1 ]
Hilgendorf, I [1 ]
Lück, A [1 ]
Junghanss, C [1 ]
Kahl, C [1 ]
Baumgart, J [1 ]
Pichlmeier, U [1 ]
Freund, M [1 ]
机构
[1] Univ Rostock, Abt Hamatol & Onkol, Fak Med, Innere Med Klin, D-18057 Rostock, Germany
关键词
D O I
10.1055/s-2005-916351
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Allogeneic transplantation can not be offered to many patients due to potential side-effects of conventional conditioning. Dose-reduced conditioning approaches improve tolerability, however, treatment efficacy may be reduced as well. We have, therefore, developed a dose intense but toxicity reduced conditioning regimen based on treosulfan and fludarabine and report first results. Patients and methods: 65 patients with a median age of 50 years were transplanted from related (n = 21) or unrelated donors (n = 44) after conditioning with treosulfan (3 x 10, 3 x 12 or 3 x 14 g/m(2) i.v.) and fludarabine (5 x 30 mg/m(2) i.v.). 21 patients were in complete remission (CR) and 44 patients had not reached a CR at the time of transplantation. 59 of 65 patients were considered unfit for a conventional conditioning regimen. Results: The actuarial overall survival after 3 years is 59.2 %, the event-free survival 40.1 %. Patients with a related donor or transplantation in CR had a better overall (85.4 resp. 74.2 %) and event-free survival (52.2 % resp. 61.9%). The cumulative incidence of relapse at 3 years was 26.2%. Non-relapse mortality a, day 100 is 17.4 % (cumulative incidence). In stepwise Cox regression analyses for overall survival, event-free survival and non-relapse mortality the covariables transplantation in CR vs. not in CR and the donor status were shown to be influential. Conclusions: These results with a conditioning therapy of treosulfan and fludarabine indicate that patients despite higher age, concomitant disease or after intensive pretreatment can be successfully transplanted without increased treatment-related mortality.
引用
收藏
页码:2125 / 2129
页数:5
相关论文
共 50 条
  • [1] Allogeneic blood stem cell transplantation after treosulfan and fludarabine conditioning
    Casper, J
    Knauf, W
    Schwenke, M
    Steiner, B
    Wolff, D
    Lueck, A
    Leithaeuser, M
    Freund, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S152 - S152
  • [2] Allogeneic haematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with haematologic malignancies
    Casper, J
    Knauf, W
    Blau, W
    Volin, L
    Ruutu, T
    Wandt, H
    Schaefer-Eckart, K
    Holowiecki, J
    Giebel, S
    Aschan, J
    Zander, A
    Kroeger, N
    Freund, M
    BONE MARROW TRANSPLANTATION, 2004, 33 : S103 - S104
  • [3] Conditioning with treosulfan and fludarabine for allogeneic blood stem cell transplantation
    Casper, J
    Steiner, B
    Wolff, D
    Kleine, HD
    Wilhelm, S
    Hammer, U
    von Wurmb, N
    Roeber, S
    Wegener, R
    Freund, M
    BONE MARROW TRANSPLANTATION, 2001, 27 : S285 - S286
  • [4] Allogeneic blood stem cell transplantation in patients with hematologic diseases after conditioning with treosulfan and fludarabine
    Casper, J
    Wilhelm, S
    Steiner, B
    Wolff, D
    Grobe, N
    Haehling, D
    Hartung, G
    Hilgendorf, I
    Lueck, A
    Junghanss, C
    Kahl, C
    Pichlmeier, U
    Freund, M
    BLOOD, 2005, 106 (11) : 770A - 770A
  • [5] Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients
    Baronciani, Donatella
    Rambaldi, Alessandro
    Iori, Anna Paola
    Di Bartolomeo, Paolo
    Pilo, Federica
    Pettinau, Martina
    Depau, Cristina
    Mico, Caterina
    Santarone, Stella
    Angelucci, Emanuele
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (09) : 717 - 720
  • [6] Allogeneic hematopoietic stem cell transplantation after Treosulfan/Fludarabine conditioning in high-risk patients with hematologic malignancies. Dose escalation of Treosulfan.
    Jochen, C
    Blau, W
    Volin, L
    Ruutu, T
    Wandt, H
    Schaefer-Eckart, K
    Holowiecki, J
    Giebel, S
    Aschan, J
    Zander, AR
    Kroeger, N
    Freund, M
    Knauf, WU
    BLOOD, 2003, 102 (11) : 467A - 467A
  • [7] Feasibilty of allogeneic haernatopoietic stem cell transplantation after dose-escalated treosulfan/fludarabine conditioning in high-risk patients with haernatologic malignancies
    Casper, J
    Blau, W
    Volin, L
    Ruutu, T
    Wandt, H
    Schäfer-Eckart, K
    Holowiecki, J
    Giebel, S
    Aschan, J
    Zander, A
    Kröger, A
    BONE MARROW TRANSPLANTATION, 2005, 35 : S203 - S203
  • [8] Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
    Nemecek, Eneida R.
    Guthrie, Katherine A.
    Sorror, Mohamed L.
    Wood, Brent L.
    Doney, Kristine C.
    Hilger, Ralf A.
    Scott, Bart L.
    Kovacsovics, Tibor J.
    Maziarz, Richard T.
    Woolfrey, Ann E.
    Bedalov, Antonio
    Sanders, Jean E.
    Pagel, John M.
    Sickle, Eileen J.
    Witherspoon, Robert
    Flowers, Mary E.
    Appelbaum, Frederick R.
    Deeg, H. Joachim
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (03) : 341 - 350
  • [9] Treosulfan in combination with fludarabine as conditioning for allogeneic stem cell transplantation in myelofibrosis
    Kragl, B.
    Heinz, F.
    Grosse-Thie, C.
    Henze, L.
    Lakner, J.
    Freitag, S.
    Wittke, C.
    Brueckner, F.
    Junghanss, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 151 - 152
  • [10] Allogeneic stem cell transplantation for lymphoma: role of conditioning with treosulfan and fludarabine
    Niittyvuopio, R.
    Heiskanen, J.
    Lindstrom, V.
    Juvonen, E.
    Nihtinen, A.
    Uotinen, H.
    Ruutu, T.
    Volin, L.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S426 - S427